TMCnet News

Biotec Pharmacon hires Jethro Holter as new Managing Director in ArcticZymes AS
[September 30, 2014]

Biotec Pharmacon hires Jethro Holter as new Managing Director in ArcticZymes AS


(Oslo Bors Newsfeed Via Acquire Media NewsEdge) Biotec Pharmacon is pleased to announce that the company has hired Mr.

Jethro Holter (42) as the new Managing Director in its subsidiary ArcticZymes AS.

Holter is today business development manager in Life Technologies (Norway) - a part of the global company Thermo Fischer Scientific - which offers high-quality, innovative life science solutions from everyday essentials to instruments - for every lab, every application.



In Life Technologies (Norway) Holter is responsible for OEM and Licensing.

Holter holds a PhD in molecular biology from University of Cardiff.


It has been crucial for the development of ArcticZymes that we get a leader with a commercial background from the molecular biology industry on board. At the same time, it has been important for us that the right candidate has the technological knowledge to understand the trends of this complicated business.

I am very satisfied that we today can demonstrate that we have found both, and I welcome Jethro to the team. Going forward, I am really looking forward to working with him, comments CEO Svein Lien in Biotec Pharmacon, who has been the acting leader in the last couple of years.

Holter will take on his position 1 January 2015. He resides in Oslo, but he will spend a lot of time at the ArcticZymes office in Tromsø.

For further information, please contact: CEO Svein W. F. Lien, +47 922 89 323.

About Biotec Pharmacon ASA: Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops and manufactures novel immunomodulating products, and has recently obtained CE-mark for Woulgan® Biogel containing its proprietary substance SBG®. Woulgan® Biogel is a primary dressing for one-time use on skin wounds, including diabetic ulcers, bedsores, leg ulcers, transplantation wounds, post -surgery wounds, trauma wounds, first- and second-degree burns, abrasions, and cuts. ArcticZymes develops, produces and sells enzymes of marine origin used in molecular DNA technologies and diagnostics, growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.

Click here for more information: http://www.newsweb.no/index.jsp?messageId=361835

[ Back To TMCnet.com's Homepage ]